GlassScriptPhysician profile
Katherine A Painter
NPI 1316145154
$7,118.87
in general payments reported to CMS, 2019-2025
17 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,006 · 2020: $1,260 · 2021: $461 · 2022: $434 · 2023: $567 · 2024: $319 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $466.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,889.61 | 2019-2021 | |
| Alcon Vision LLC | $1,378.60 | 2020-2025 | Tryptyr, Precision7, Rocklatan |
| Sight Sciences, INC. | $959.76 | 2019-2025 | Tearcare System |
| Coopervision INC. | $616.52 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $477.48 | 2020-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $396.50 | 2019-2022 | |
| Abbvie INC. | $312.56 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $286.33 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $182.06 | 2022-2025 | Infuse, Miebo, Xiidra |
| Osmotica Pharmaceutical Corp. | $136.31 | 2019 | |
| Dompe US, INC. | $125.11 | 2023-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $98.11 | 2021-2022 | |
| Genentech USA, INC. | $94.78 | 2019 | |
| Allergan, INC. | $54.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $53.68 | 2025 | Xdemvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $47.90 | 2025 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $9.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Painter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.